Course Opens
10/01/2024
Credits
1
Credit Expires
10/01/2025
The reduced incidence of cervical cancer over the past few decades was primarily due to robust screening guidelines and vaccinations. However, despite the proliferation of screening programs, the diagnosis of cervical cancer is associated with inefficiencies and inconsistencies and has not decreased cervical cancer incidence further over the past decade. Additionally, numerous health care disparities persist as unaddressed medical needs, particularly for individuals with marginalized sexualities and genders. An exciting array of new immunotherapy options are further emerging for patients with locally advanced, recurrent, or metastatic cervical cancer, with promising potential to heighten treatment effectiveness. It is imperative that clinicians and the multidisciplinary care team are appraised on these novel therapies and are conscious of health care disparities and unique patient needs.
In this CE Concepts recorded webcast, expert faculty will guide learners on the implementation of recommended, inclusive, and universal screening techniques and programs for cervical cancer. Faculty will also evaluate the latest efficacy and safety data in different settings for the treatment of cervical cancer as well as incorporate actionable strategies to address disparities and the unique health care of individuals with marginalized sexualities and genders related to cervical cancer screening.
At the conclusion of this activity, learners will be able to better:
Supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.
Gynecologic oncologists, OB/GYNs, physician associates (PAs), nurse practitioners (NPs), and nurses caring for patients with cervical cancer
In support of improving patient care, Creative Educational Concepts, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Creative Educational Concepts, LLC, designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is designated for 1.00 contact hours.
Note to Nurse Practitioners: The content of this CNE activity pertains to Pharmacology.
This activity is designated for 1.00 contact hours.
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points in the following ILNA subject areas:
OCN®️
Care Continuum Patient
Oncology Nursing Practice
Psychosocial Dimensions of Care
Treatment
CBCN®️
Care Continuum
Psychosocial Dimensions of Care
Treatment
CPHON®️
Care Continuum
Psychosocial Dimensions of Care
Treatment
AOCNP*
Care Continuum
Professional Practice /Performance
Psychosocial Dimensions of Care
Roles of the APRN
Treatment
BMTCN®️
Professional Practice /Performance
Disclaimer: ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education Credit for learning and change.
Creative Educational Concepts, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. Approval is valid until 09/24/2025. PAs should only claim credit commensurate with the extent of their participation.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Dr. Colombo reports the following financial relationships:
Advisory Board: AstraZeneca; Clovis Oncology, Inc.; Eisai Co., Ltd; GSK; ImmunoGen, Inc.; Mersana Therapeutics; MSD/Merck & Co., Inc.; Novocure; Nuvation Bio Inc.; OncXerna Therapeutics, Inc.; Pieris Pharmaceuticals, Inc.; and Roche
Grants: AstraZeneca; GSK; and Roche
Research Support: GSK
Speakers Bureau: AstraZeneca; Clovis Oncology, Inc.; MSD/Merck & Co., Inc.; GSK; and Eisai Co., Ltd
Dr. Aleshire reports no financial relationships to disclose.
Dr. Monk reports the following financial relationships:
Consultant: Acrivon Therapeutics; Adaptimmune; Amgen Inc.; AstraZeneca; Biohaven, Ltd; BioNTech SE; Bristol Myers Squibb Company; Corcept Therapeutics; Eisai Inc.; Lilly; Genmab/Seagen Inc./Pfizer Inc.; Genelux Corporation; GOG Foundation Inc.; Gradalis, Inc.; GSK; Hengrui; ImmunoGen, Inc./AbbVie Inc.; Karyopharm; Iovance Biotherapeutics, Inc.; Merck & Co., Inc.; Mersana Therapeutics; Mursla Inc./Alkermes; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Novocure; OncoC4; Panavance Therapeutics Inc.; ProfoundBio; Regenron Pharmaceuticals Inc./Genmab; Roche/Genetech, Inc.; Sutro Biopharma, Inc.; Verastem, Inc.; Zentalis Pharmaceuticals; and Zymeworks Inc.
Speakers Bureau: AstraZeneca; Eisai Inc.; GSK; ImmunoGen, Inc./AbbVie Inc.; and Merck & Co., Inc.
The following individuals have no financial relationships to disclose:
Alaa Bawaneh, MD, PhD (Peer Reviewer)
Michael Franks, APRN, AGACNP-BC, FNP-BC (Peer Reviewer)
Keshia Pitt, PhD (Planning Committee)
David Modrak, PhD (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)
Post-tests, credit request forms, and activity evaluations must be completed online
(requires free account activation), and participants can print their certificate or statement of
credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac.
Visit the Creative Educational Concepts Privacy Policy page for complete information about our privacy policy and practices.
Call us at 859-260-1717 • info@ceconcepts.com
WCV-086-100124-44
Call us at 859-260-1717 • info@ceconcepts.com